Eltrombopag in Good’s Syndrome

Abstract EN

Good’s syndrome is a rare acquired immunodeficiency associated with thymoma.

Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias.

In this paper, we describe a male patient suffering from Good’s syndrome with immune-mediated T-cell driven pancytopenia and absence of megakaryopoiesis.

He was successfully treated with eltrombopag resulting in a multilineage clinical response.